Cariprazine for Treating Schizophrenia, Mania, Bipolar Depression, and Unipolar Depression: A Review of Its Efficacy

被引:4
作者
Tarzian, Martin [1 ]
Ndrio, Mariana [2 ]
Kaja, Srujan [3 ]
Beason, Elisabeth [4 ]
Fakoya, Adegbenro O. [5 ]
机构
[1] Univ Med & Hlth Sci, Psychiat, Basseterre, St Kitts & Nevi
[2] Univ Med & Hlth Sci, Psychiat & Behav Sci, Basseterre, St Kitts & Nevi
[3] Larkin Community Hosp, Psychiat, Miami, FL USA
[4] Univ Med & Hlth Sci, Cardiol, Basseterre, St Kitts & Nevi
[5] Louisiana State Univ Hlth Sci Ctr, Cellular Biol & Anat, Shreveport, LA 71103 USA
关键词
psychiatric disorders; bipolar depression; unipolar depression; major depression; schizophrenia; cariprazine; DOUBLE-BLIND; ACUTE EXACERBATION; POOLED ANALYSIS; I DISORDER; PHASE-II; SAFETY; TOLERABILITY; RECEPTOR;
D O I
10.7759/cureus.39309
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This drug review presents a comprehensive review of Cariprazine, a medication that received FDA approval in 2015 for treating schizophrenia and bipolar disorder. The paper begins by exploring Cariprazine's mechanism of action, which involves modulating dopamine and serotonin receptors. Additionally, the review assesses Cariprazine's metabolic profile and notes its low potential for weight gain and metabolic side effects. The study examines Cariprazine's efficacy and safety in treating various psychiatric disorders, such as schizophrenia, bipolar maintenance, mania, and bipolar depression. A meticulous analysis of clinical trials is included, demonstrating Cariprazine's potential advantages over existing medications used for these disorders. Additionally, the review covers Cariprazine's recent approval as an adjuvant treatment for unipolar depression. Furthermore, the paper examines the limitations of Cariprazine, such as the absence of head-to-head trials comparing it to other commonly used medications for these disorders. The paper concludes by emphasizing the need for more research to establish Cariprazine's position in treating schizophrenia and bipolar disorder and determine its comparative effectiveness with other available treatments.
引用
收藏
页数:16
相关论文
共 48 条
[1]  
[Anonymous], 2012, CARIPRAZINE EXHIBITS
[2]  
[Anonymous], 2020, DEPRESSIVE DISORDERS
[3]  
[Anonymous], 2020, BIPOLAR DISORDER LEV
[4]  
[Anonymous], 2020, SCHIZOPHRENIA LEVEL
[5]  
[Anonymous], 2022, DRUGS FDA DATA FILES
[6]  
[Anonymous], 2022, World Health Organization Internet
[7]   Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists [J].
Artigas, F ;
Romero, L ;
deMontigny, C ;
Blier, P .
TRENDS IN NEUROSCIENCES, 1996, 19 (09) :378-383
[8]   A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia [J].
Caccia, Silvio ;
Invernizzi, Roberto William ;
Nobili, Alessandro ;
Pasina, Luca .
THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2013, 9 :319-328
[9]   Efficacy and Safety of Low- and High-Dose Cariprazine in Acute and Mixed Mania Associated With Bipolar I Disorder: A Double-Blind, Placebo-Controlled Study [J].
Calabrese, Joseph R. ;
Keck, Paul E., Jr. ;
Starace, Anju ;
Lu, Kaifeng ;
Ruth, Adam ;
Laszlovszky, Istvan ;
Nemeth, Gyoergy ;
Durgam, Suresh .
JOURNAL OF CLINICAL PSYCHIATRY, 2015, 76 (03) :284-292
[10]   Serotonin 5-HT1A Receptors as Targets for Agents to Treat Psychiatric Disorders: Rationale and Current Status of Research [J].
Celada, Pau ;
Bortolozzi, Analia ;
Artigas, Francesc .
CNS DRUGS, 2013, 27 (09) :703-716